STAT3 and urinary bladder cancer: Alcantara et al. (2023) further demonstrated that targeting STAT3 activation in MDSCs through CpG-STAT3 antisense oligonucleotide (ASO) therapy significantly reduces immunosuppression and enhances T-cell activity in renal and bladder cancer.